98%
921
2 minutes
20
Background: Cyclosporine's narrow therapeutic index and pharmacokinetic variability challenge its optimal dosing in renal transplantation. Model-informed precision dosing (MIPD), utilizing population pharmacokinetic (popPK) models and Bayesian forecasting, can enhance dosing optimization and improve clinical outcomes. This study evaluated the predictive performance of published popPK models and multi-model strategies for cyclosporine, using therapeutic drug monitoring (TDM) data and full pharmacokinetic (PK) profiles.
Methods: We evaluated 15 published popPK models and 2 multi-model strategies (averaging/selection) using TDM data (1,856 concentrations from 114 patients) and full-PK profiles (259 concentrations from 24 patients). Bayesian forecasting with objective function value (OFV)- and Akaike information criterion (AIC)-based weighting was applied to predict cyclosporine peak concentration (C₂) and area under the curve (AUC). Predictive accuracy and precision were assessed using relative bias (rBias) and relative root mean square error (rRMSE).
Results: The two-compartment model with first-order absorption and transit compartments (Press et al., 2010) provided the best prediction for C₂ (rBias = -1.40%, rRMSE = 5.38%), while the model with lag time and covariates postoperative days, age, and weight (Baek et al., 2014) excelled in AUC prediction (rBias = 4.82%, rRMSE = 1.92%). Multi-model averaging/selection performed comparably to top-performing single popPK models for C₂ (rBias <10% with OFV-based weighting) but underperformed for AUC prediction (rBias >20%).
Conclusion: While single popPK models provide reliable predictions for specific PK endpoints, multi-model strategies do not consistently outperform individual models. The optimal model selection for MIPD should be fit-for-purpose to ensure optimal cyclosporine dosing and improved clinical outcomes in renal transplantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejps.2025.107241 | DOI Listing |
Adv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Int J Antimicrob Agents
September 2025
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan
Objectives: The pharmacokinetics of renally cleared vancomycin are significantly altered in critically ill patients undergoing renal replacement therapy (RRT), affecting the achievement of therapeutic targets. We evaluated the predictive performance of RRT patient-based PopPK models for model-informed precision dosing and subsequently simulated optimal dosing regimens for this population.
Methods: Six adult PopPK models were systematically identified and evaluated using a dataset of 226 concentrations from 23 adult patients on RRT from two study centers.
Int J Antimicrob Agents
September 2025
Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China; Research Ward of Huashan Hospital, Fudan University, Shanghai 200040, China. Elec
Eravacycline is a tetracycline used for the treatment of complicated intra-abdominal infections (cIAI) and has the potential to treat community-acquired bacterial pneumonia (CABP). The approved regimen for cIAI is 1mg/kg (Q12h). However, studies have reported the inconvenience of drug preparation based on body weight (BW) and wastage of the drug, because the specification is 50 mg per vial.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Immunosuppressive therapy remains the primary method for preventing rejection in renal transplant recipients. While multiple population pharmacokinetic (popPK) models of mycophenolate sodium (MPS) have been developed for this population, their predictive performance across different clinical settings remains unverified. This study systematically evaluated published MPS popPK models through external validation to assess their extrapolation potential.
View Article and Find Full Text PDFAntimicrob Agents Chemother
September 2025
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
This study aimed to develop population pharmacokinetic (PopPK) models for intravenous sulfamethoxazole (SMX) and trimethoprim (TMP) to optimize dosing regimens for the treatment of pneumonia using these models. A prospective study was conducted in 79 patients treated with intravenous trimethoprim-sulfamethoxazole. PopPK models were developed using nonlinear mixed-effect modeling to evaluate the effects of liver function, kidney function, and genetic polymorphisms ( and ) on pharmacokinetic parameters.
View Article and Find Full Text PDF